10.6084/m9.figshare.1569651.v4 Nishi Kothari Nishi Kothari Richard Kim Richard Kim Robert N. Jorissen Robert N. Jorissen Jayesh Desai Jayesh Desai Jeanne Tie Jeanne Tie Hui-Li Wong Hui-Li Wong Ian Farragher Ian Farragher Ian Jones Ian Jones Fiona L. Day Fiona L. Day Shan Li Shan Li Anuratha Sakthinandeswaren Anuratha Sakthinandeswaren Michelle Palmieri Michelle Palmieri Lara Lipton Lara Lipton Michael Schell Michael Schell Jamie K. Teer Jamie K. Teer David Shibata David Shibata Timothy Yeatman Timothy Yeatman Oliver M. Sieber Oliver M. Sieber Peter Gibbs Peter Gibbs Ben Tran Ben Tran Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation Taylor & Francis Group 2015 Multivariate survival analyses Royal Melbourne Hospital Regular aspirin use PIK 3CA tumors hr colorectal cancer Prospective clinicopathological data Moffitt Cancer Center PIK 3CA CRC patients PIK 3CA mutation PIK 3CA mutation Background aspirin use rmh PIK 3CA CRC.Patients 1487 CRC patients mcc PIK 3CA CRC Generation Sequencing platform PIK 3CA mutations 2015-10-08 17:11:55 Journal contribution https://tandf.figshare.com/articles/journal_contribution/Impact_of_regular_aspirin_use_on_overall_and_cancer_specific_survival_in_patients_with_colorectal_cancer_harboring_a_PIK3CA_mutation/1569651 <div><p></p><p><b>Background.</b> Recent data have suggested that regular aspirin use improves overall and cancer-specific survival in the subset of colorectal cancer (CRC) patients harboring <i>PIK3CA</i> mutations. However, the number of <i>PIK3CA</i>-mutated CRC patients examined in these studies was modest. Our collaborative study aims to validate the association between regular aspirin use and survival in patients with <i>PIK3CA</i>-mutated CRC.</p><p><b>Patients and methods.</b> Patients with <i>PIK3CA</i>-mutated CRC were identified at Moffitt Cancer Center (MCC) in the United States and Royal Melbourne Hospital (RMH) in Australia. Prospective clinicopathological data and survival data were available. At MCC, <i>PIK3CA</i> mutations were identified by targeted exome sequencing using the Illumina GAIIx Next Generation Sequencing platform. At RMH, Sanger sequencing was utilized. Multivariate survival analyses were conducted using Cox logistic regression.</p><p><b>Results.</b> From a cohort of 1487 CRC patients, 185 patients harbored a <i>PIK3CA</i> mutation. Median age of patients with PIK3CA-mutated tumors was 72 years (range: 34–92) and median follow up was 54 months. Forty-nine (26%) patients used aspirin regularly. Regular aspirin use was not associated with improved overall survival (multivariate HR 0.96, p = 0.86). There was a trend towards improved cancer-specific survival (multivariate HR 0.60, p = 0.14), but this was not significant.</p><p><b>Conclusions.</b> Despite examining a large number of patients, we did not confirm that regular aspirin use was associated with statistically significant improvements in survival in PIK3CA-mutated CRC patients. Prospective evaluation of this relationship is warranted.</p></div>